Revolo Biotherapeutics


They are a revolutionary biotherapeutics company and their mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.

Their two platform drug candidates, ‘1805 and ‘1104, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies without immune suppression. Given Revolo's disease-agnostic approach, they are uniquely positioned as Revolutionaries in the development of drugs for various autoimmune and allergic diseases.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.